Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology
Kestra’s ASSURE WCD delivers 100% shock success in the largest real-world study to date.
What the company is saying
Kestra Medical Technologies is highlighting the publication of primary results from the ACE-PAS study, which it frames as the largest prospective real-world evaluation of wearable cardioverter defibrillators, enrolling 21,612 patients across 35 U.S. states. The company emphasizes that the ASSURE WCD achieved 100% all-shock conversion success and met both primary safety and effectiveness endpoints, positioning this as a major validation of its technology. The announcement stresses the low inappropriate-shock rate of 0.0065 per patient-month and that 94% of patients experienced no false-positive shock alarms, underscoring patient comfort and device reliability. Kestra also draws attention to high patient adherence, with a median daily wear time of 23.1 hours and 30% of patients continuing use beyond 90 days. The messaging is confident, with CEO Brian Webster calling the results an important milestone for wearable defibrillator therapy, and Principal Investigator Dr. Jeanne E. Poole reinforcing the clinical need for WCD protection during cardiac recovery. The company also introduces a new detection algorithm, projecting a further 70% reduction in inappropriate shocks, but this is presented as a forward-looking improvement rather than a realised outcome.
What the data suggests
The ACE-PAS study enrolled 21,612 patients between November 2021 and July 2025, making it the largest real-world WCD study to date. ASSURE WCD achieved 100% conversion of all 303 analyzable VT/VF shock events, meeting the primary effectiveness endpoint. The inappropriate-shock rate was 0.0065 per patient-month, outperforming the prespecified safety goal, and 94% of patients experienced no false-positive shock alarms, indicating a low alarm burden. Median daily wear was 23.1 hours, with 30% of patients maintaining use beyond 90 days, demonstrating strong adherence. 2.6% of patients experienced at least one VT/VF event, with 55% of episodes occurring in the first month, but risk persisted over subsequent months. Among patients with LVEF ≤35% and primary-prevention criteria, the 90-day VT/VF risk was 3.2% post-myocardial infarction, 2.8% in ischemic cardiomyopathy, and 2.5% in nonischemic cardiomyopathy. The enhanced detection algorithm introduced in April 2026 is projected to reduce the inappropriate shock rate by nearly 70%, from 0.0065 to 0.0020 per patient-month, but no realised post-implementation data are disclosed. All clinical and operational metrics are clearly reported, but there are no financial figures or commercial uptake data.
Analysis
The announcement is largely factual and data-driven, reporting the publication of primary results from a large, FDA-mandated clinical study with clear, realised safety and effectiveness outcomes for the ASSURE WCD. The majority of claims are supported by specific, realised clinical data (e.g., 100% conversion success, 0.0065 inappropriate-shock rate, 94% no false-positive alarms). However, the introduction of an enhanced detection algorithm in April 2026 is accompanied by forward-looking projections (a 70% reduction in inappropriate shock rate) without realised post-implementation data, which slightly inflates the narrative. There is no mention of financial metrics, commercial uptake, or profitability, so the true_signal cannot exceed weak_positive. The hype level is moderate due to the inclusion of projected benefits and aspirational statements about future improvements, but the bulk of the announcement is grounded in realised clinical evidence. No large capital outlay or long-dated, uncertain returns are discussed.
Risk flags
- ●The projected 70% reduction in inappropriate shock rate with the enhanced algorithm is not yet supported by post-implementation data, introducing uncertainty about whether this benefit will be realised in practice.
- ●No financial, revenue, or commercial adoption data are disclosed, so the impact of these clinical results on Kestra’s business trajectory and market penetration remains unclear.
- ●While the study demonstrates strong clinical performance, ongoing risk of VT/VF events beyond the first month (2.6% of patients affected, with 45% of events after month one) means sustained patient adherence is critical for real-world effectiveness.
- ●The announcement does not address potential regulatory, reimbursement, or competitive risks that could affect the commercialisation or uptake of the ASSURE WCD despite strong clinical evidence.
Bottom line
Kestra’s ASSURE WCD has demonstrated 100% shock conversion success and a low inappropriate-shock rate in a 21,612-patient, FDA-mandated real-world study, providing robust clinical validation for the device. Patient adherence was high, with a median of 23.1 hours daily wear and 30% continuing beyond 90 days, while 94% experienced no false-positive shock alarms. The company projects a further 70% reduction in inappropriate shocks with a new detection algorithm launched in April 2026, but no realised outcome data are available for this enhancement. No financial, revenue, or commercial uptake figures are disclosed, so the direct business impact remains unquantified. The key takeaway is that ASSURE WCD is now backed by the largest real-world dataset for its class, but investors will need to watch for future updates on commercial adoption, payer coverage, and realised post-enhancement outcomes to gauge financial upside.
Announcement summary
(NASDAQ:KMTS) Kestra Medical Technologies, Ltd. announced the publication of primary results from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) in the Journal of Cardiovascular Electrophysiology. ACE-PAS is the largest prospective real-world study of wearable cardioverter defibrillators (WCD) to date, enrolling 21,612 patients across 35 U.S. states. The study met both its primary safety and effectiveness endpoints. The ASSURE WCD achieved 100% all-shock conversion success, converting all 303 analyzable VT/VF shock events with one or more shocks. The inappropriate-shock rate was 0.0065 per patient-month, outperforming the prespecified safety performance goal. 94% of patients experienced no false-positive shock alarms, supporting a better patient experience and enabling sustained wear. Patients wore the ASSURE device for a median of 23.1 hours per day, with 30% continuing use beyond 90 days while maintaining the same median daily wear time. 2.6% of patients experienced at least one shocked or unshocked VT/VF event, with 55% of episodes occurring during the first month. Among patients with LVEF ≤35% who met primary-prevention criteria for sudden cardiac death, the estimated risk of experiencing VT/VF within 90 days was 3.2% following myocardial infarction, 2.8% in ischemic cardiomyopathy, and 2.5% in nonischemic cardiomyopathy. Kestra introduced an enhanced detection algorithm for the ASSURE WCD in April 2026, which is projected to reduce the inappropriate shock rate by nearly 70%, from 0.0065 to 0.0020 per patient-month. The ACE-PAS study was FDA-mandated, prospective, and single-arm, evaluating the safety and effectiveness of the ASSURE Wearable Cardioverter Defibrillator in routine clinical use. The study included patients fitted between November 2021 and July 2025. Brian Webster, President and CEO of Kestra Medical Technologies, stated that the publication of ACE-PAS results marks an important milestone in advancing the evidence base for wearable defibrillator therapy and monitoring. Jeanne E. Poole, MD, Professor of Medicine at the University of Washington and Principal Investigator, commented on the importance of WCD protection during the recovery period after myocardial infarction or new heart failure diagnosis.
Disagree with this article?
Ctrl + Enter to submit